[{"address1": "35 Gatehouse Drive, A2", "city": "Waltham", "state": "MA", "zip": "02451", "country": "United States", "phone": "781 996 0955", "website": "https://www.morphictx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4\u00df7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4\u00df7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; av\u00df8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schr\u00f6dinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 124, "companyOfficers": [{"maxAge": 1, "name": "Dr. Bruce N. Rogers Ph.D.", "age": 54, "title": "President", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 857340, "exercisedValue": 0, "unexercisedValue": 3395228}, {"maxAge": 1, "name": "Dr. Marc  Schegerin M.B.A., M.D.", "age": 47, "title": "CFO & COO", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 769252, "exercisedValue": 0, "unexercisedValue": 533936}, {"maxAge": 1, "name": "Mr. Robert E. Farrell Jr., CPA", "age": 58, "title": "Senior VP of Finance & Chief Accounting Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 645500, "exercisedValue": 0, "unexercisedValue": 1715749}, {"maxAge": 1, "name": "Dr. Blaise  Lippa Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. William D. DeVaul Esq.", "age": 52, "title": "General Counsel & Secretary", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 601440, "exercisedValue": 4317338, "unexercisedValue": 4829301}, {"maxAge": 1, "name": "Mr. Aaron  Pelta", "title": "Senior Vice President of Business & Corporate Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Joanne  Gibbons", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Simon  Cooper MBBS", "age": 53, "title": "Chief Medical Officer", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1719792000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 56.53, "open": 56.52, "dayLow": 56.43, "dayHigh": 56.58, "regularMarketPreviousClose": 56.53, "regularMarketOpen": 56.52, "regularMarketDayLow": 56.43, "regularMarketDayHigh": 56.58, "beta": 1.491, "forwardPE": -13.337265, "volume": 1486959, "regularMarketVolume": 1486959, "averageVolume": 2125219, "averageVolume10days": 3077900, "averageDailyVolume10Day": 3077900, "bid": 40.67, "ask": 72.34, "bidSize": 200, "askSize": 200, "marketCap": 2833194496, "fiftyTwoWeekLow": 19.345, "fiftyTwoWeekHigh": 62.08, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 36.9097, "twoHundredDayAverage": 30.905325, "currency": "USD", "enterpriseValue": 2177307392, "floatShares": 33805157, "sharesOutstanding": 50100700, "sharesShort": 5961199, "sharesShortPriorMonth": 6172301, "sharesShortPreviousMonthDate": 1717113600, "dateShortInterest": 1719532800, "sharesPercentSharesOut": 0.118999995, "heldPercentInsiders": 0.17265, "heldPercentInstitutions": 0.99333, "shortRatio": 9.4, "shortPercentOfFloat": 0.23809999, "impliedSharesOutstanding": 50100700, "bookValue": 13.247, "priceToBook": 4.268891, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -161254000, "trailingEps": -3.6, "forwardEps": -4.24, "enterpriseToEbitda": -11.342, "52WeekChange": 0.06137383, "SandP52WeekChange": 0.19608545, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "MORF", "underlyingSymbol": "MORF", "shortName": "Morphic Holding, Inc.", "longName": "Morphic Holding, Inc.", "firstTradeDateEpochUtc": 1561642200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "a1e60ff9-744a-3908-a947-e5d2f0a617cc", "messageBoardId": "finmb_345057935", "gmtOffSetMilliseconds": -14400000, "currentPrice": 56.55, "targetHighPrice": 64.0, "targetLowPrice": 40.0, "targetMeanPrice": 56.13, "targetMedianPrice": 57.0, "recommendationMean": 2.7, "recommendationKey": "hold", "numberOfAnalystOpinions": 8, "totalCash": 658766016, "totalCashPerShare": 13.151, "ebitda": -191968992, "totalDebt": 3281000, "quickRatio": 37.195, "currentRatio": 38.165, "debtToEquity": 0.494, "returnOnAssets": -0.21459, "returnOnEquity": -0.29584998, "freeCashflow": -74944128, "operatingCashflow": -127247000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-25"}]